NovaGo Therapeutics
www.novagotherapeutics.comNovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.
Read more
NovaGo’s fully human monoclonal antibodies have the potential to become a safe and effective treatment in central nervous system indications. NovaGo’s proprietary antibodies block the function of Nogo-A, one of the most potent and well-studied vascular and nerve growth inhibitors.
Read more
Country
Industry
Employees
1-10
Founded
2015
Estimated Revenue
$1 to $1,000,000
Social
Employees statistics
View all employeesPotential Decision Makers
Chief Executive Officer
Email ****** @****.comPhone (***) ****-****Principal Scientist Antibody Development
Email ****** @****.comPhone (***) ****-****
Technologies
(9)
Reach decision makers at NovaGo Therapeutics
Free credits every month!
NovaGo Therapeutics FAQ
Biotechnology Research
